第一医药(600833) - 2020 Q1 - 季度财报

Financial Performance - Operating revenue rose by 63.02% to CNY 502,080,000.94 year-on-year, primarily due to increased sales of epidemic prevention products[9] - Net profit attributable to shareholders increased by 32.02% to CNY 18,638,693.76 compared to the same period last year[5] - Total operating revenue for Q1 2020 reached ¥502,080,000.94, a 63.1% increase from ¥307,984,638.80 in Q1 2019[20] - Net profit for Q1 2020 was ¥18,638,693.76, representing a 32.5% increase compared to ¥14,117,679.49 in Q1 2019[20] - Basic and diluted earnings per share for Q1 2020 were both ¥0.0835, compared to ¥0.0633 in Q1 2019[20] Assets and Liabilities - Total assets increased by 21.53% to CNY 1,478,514,437.09 compared to the end of the previous year[5] - The company's current assets reached CNY 1,120,622,926.71, up from CNY 849,159,666.66 at the end of 2019, indicating a rise of about 32%[14] - Total liabilities increased to CNY 732,673,614.46 from CNY 484,214,594.76, representing a growth of approximately 51.4%[15] - Current liabilities totaled CNY 672,478,761.33, up from CNY 422,230,117.31, indicating an increase of approximately 59.2%[15] - Total liabilities as of Q1 2020 amounted to ¥626,281,808.29, significantly higher than ¥309,005,285.76 in the previous year[18] Cash Flow - Cash flow from operating activities showed a significant decline of 189.93%, resulting in a net outflow of CNY 41,922,771.04[9] - Cash flow from operating activities showed a net outflow of ¥41.92 million in Q1 2020, compared to a net inflow of ¥46.62 million in Q1 2019[23] - The net cash flow from operating activities was negative at -¥86,421,552.25, a significant decline from a positive net cash flow of ¥45,253,757.10 in the same period last year[24] - The overall net increase in cash and cash equivalents for Q1 2020 was ¥89,437,928.97, compared to an increase of ¥45,182,773.04 in Q1 2019[24] Inventory and Receivables - Inventory increased by 47.41% to CNY 325,379,426.91, mainly due to the rise in stock of epidemic prevention products[9] - Accounts receivable rose to CNY 142,512,135.64 from CNY 116,978,046.81, marking an increase of around 21.8%[14] - The company reported a significant increase in prepayments by 2955.91% to CNY 52,042,210.09, reflecting increased advance payments for epidemic prevention products[9] Shareholder Information - The number of shareholders totaled 24,945, with the largest shareholder holding 44.95% of the shares[7] - The company's equity attributable to shareholders rose to CNY 738,833,506.74 from CNY 725,329,730.23, showing a slight increase of about 1.9%[15] Operational Challenges - The company faces uncertainties in operations due to external factors such as economic slowdown and supply chain disruptions[9] Research and Development - The company incurred R&D expenses but did not disclose specific figures in the report[21] Future Plans - The company plans to focus on market expansion and new product development in the upcoming quarters, although specific figures were not disclosed[20]